Diazepam Trial in GAD65 Associated Epilepsy
Primary Purpose
GAD 65 Antibody-associated Epilepsy
Status
Enrolling by invitation
Phase
Phase 1
Locations
United States
Study Type
Interventional
Intervention
Diazepam
Sponsored by
About this trial
This is an interventional treatment trial for GAD 65 Antibody-associated Epilepsy
Eligibility Criteria
Inclusion Criteria:
- High-titer serum GAD65 positivity > 20 nmol/L High-titer serum GAD65 IgG seropositivity titer >20 nmol/L and/or CSF GAD65 seropositivity titer > 0.02 nmol/L.
- Drug-resistant focal epilepsy, having failed 2 previous anti-seizure medications.
- Stable treatment for the 1 month prior to enrollment.
- Patients must be able to give informed consent or have an appropriate representative available to do.
Exclusion Criteria:
- Alternative etiology for epilepsy.
- Already on another benzodiazepine.
- On a regularly scheduled opiate.
- Co-existing antibodies associated with seizures.
- Pregnancy or breast feeding.
Sites / Locations
- Mayo Clinic in Rochester
Arms of the Study
Arm 1
Arm Type
Experimental
Arm Label
GAD65 Associated Epilepsy
Arm Description
Subjects diagnosed with GAD65 associated epilepsy, serum high-titer GAD65 positivity, trialed and failed at least 2 anti-seizure medications, at least 4 seizures per month will be started on diazepam.
Outcomes
Primary Outcome Measures
Change in seizure frequency
Median percentage change in the mean monthly frequency of seizures as measured by patient recorded seizure frequency
Secondary Outcome Measures
Full Information
1. Study Identification
Unique Protocol Identification Number
NCT05361447
Brief Title
Diazepam Trial in GAD65 Associated Epilepsy
Official Title
Open Label Single Center Trial Evaluating the Efficacy and Safety of Diazepam in GAD65 Associated Epilepsy
Study Type
Interventional
2. Study Status
Record Verification Date
February 2023
Overall Recruitment Status
Enrolling by invitation
Study Start Date
January 11, 2023 (Actual)
Primary Completion Date
December 2023 (Anticipated)
Study Completion Date
December 2023 (Anticipated)
3. Sponsor/Collaborators
Responsible Party, by Official Title
Principal Investigator
Name of the Sponsor
Mayo Clinic
4. Oversight
Studies a U.S. FDA-regulated Drug Product
Yes
Studies a U.S. FDA-regulated Device Product
No
Data Monitoring Committee
No
5. Study Description
Brief Summary
The purpose of this study is to determine whether diazepam reduces the frequency of seizures in GAD65 antibody associated epilepsy.
Detailed Description
GAD65 is an intracellular enzyme that plays a key role in the conversion of glutamate to gamma-aminobutyric acid (GABA), the primary inhibitory neurotransmitter in the CNS. Benzodiazepines augment the sensitivity of the GABA-A receptor to GABA, prolonging its inhibitory effect, perhaps enhancing the potential for neural inhibition in conditions in which GABA is depleted.
GAD65 antibodies have been identified in a subset of patients with drug resistant focal epilepsy and limbic encephalitis. While it has not been definitively determined that these antibodies cause GAD65 inhibition and GABA depletion directly, diazepam, a common benzodiazepine, has been established as a mainstay of therapy for stiffperson's syndrome, a condition that is commonly associated with GAD65 antibody positivity. Given these observations, diazepam has been used by the investigators in a small number of patients with intractable epilepsy in the setting of GAD65 antibody positivity, with some encouraging anecdotal results with one patient being rendered seizure free for three years.
The purpose of this study is to generate prospective data on use of diazepam in patients with epilepsy related to high-titer GAD65 antibody positivity.
6. Conditions and Keywords
Primary Disease or Condition Being Studied in the Trial, or the Focus of the Study
GAD 65 Antibody-associated Epilepsy
7. Study Design
Primary Purpose
Treatment
Study Phase
Phase 1, Phase 2
Interventional Study Model
Single Group Assignment
Masking
None (Open Label)
Allocation
N/A
Enrollment
30 (Anticipated)
8. Arms, Groups, and Interventions
Arm Title
GAD65 Associated Epilepsy
Arm Type
Experimental
Arm Description
Subjects diagnosed with GAD65 associated epilepsy, serum high-titer GAD65 positivity, trialed and failed at least 2 anti-seizure medications, at least 4 seizures per month will be started on diazepam.
Intervention Type
Drug
Intervention Name(s)
Diazepam
Other Intervention Name(s)
Valium
Intervention Description
5 mg twice daily oral for 1 week and then increase to 10 mg twice daily oral
Primary Outcome Measure Information:
Title
Change in seizure frequency
Description
Median percentage change in the mean monthly frequency of seizures as measured by patient recorded seizure frequency
Time Frame
Baseline, 3 months
10. Eligibility
Sex
All
Minimum Age & Unit of Time
18 Years
Accepts Healthy Volunteers
No
Eligibility Criteria
Inclusion Criteria:
High-titer serum GAD65 positivity > 20 nmol/L High-titer serum GAD65 IgG seropositivity titer >20 nmol/L and/or CSF GAD65 seropositivity titer > 0.02 nmol/L.
Drug-resistant focal epilepsy, having failed 2 previous anti-seizure medications.
Stable treatment for the 1 month prior to enrollment.
Patients must be able to give informed consent or have an appropriate representative available to do.
Exclusion Criteria:
Alternative etiology for epilepsy.
Already on another benzodiazepine.
On a regularly scheduled opiate.
Co-existing antibodies associated with seizures.
Pregnancy or breast feeding.
Overall Study Officials:
First Name & Middle Initial & Last Name & Degree
Kelsey Smith, MD
Organizational Affiliation
Mayo Clinic
Official's Role
Principal Investigator
Facility Information:
Facility Name
Mayo Clinic in Rochester
City
Rochester
State/Province
Minnesota
ZIP/Postal Code
55905
Country
United States
12. IPD Sharing Statement
Links:
URL
https://www.mayo.edu/research/clinical-trials
Description
Mayo Clinic Clinical Trials
Learn more about this trial
Diazepam Trial in GAD65 Associated Epilepsy
We'll reach out to this number within 24 hrs